Details of the Drug
General Information of Drug (ID: DM4N7BT)
Drug Name |
Paritaprevir
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
(2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; ABT 450; ABT-450; ABT450; CHEMBL3391662; EX-A2278; OU2YM37K86; Paritaprevir; Paritaprevir [USAN:INN]; Paritaprevir(ABT-450); Paritaprevir(Veruprevir ABT-450); SCHEMBL3069964; UNII-OU2YM37K86; Veruprevir; Veruprevir [INN]; Veruprevir anhydrous
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Therapeutic Class |
Antiviral Agent
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 1 |
Molecular Weight | 765.886 | |||||||||||||||||||||
Logarithm of the Partition Coefficient | Not Available | ||||||||||||||||||||||
Rotatable Bond Count | 7 | ||||||||||||||||||||||
Hydrogen Bond Donor Count | 3 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count | 10 | ||||||||||||||||||||||
ADMET Property |
|
||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | ||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Transporter (DTP) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||